Skip to main content

Table 2 Clinical characteristics of prostate cancer patients according to PLR

From: Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy

Parameters

PLR

P-value

<117.58 (n = 146 50.34 %)

≥117.58 (n = 144 49.66 %)

Age (median, interquartile range), years

76 (66–79)

75 (68–80)

0.632

PSA (median, interquartile range), μg/L

100.00 (28.30–170.00)

100.00 (33.05–213.00)

0.625

Gleason Score (≤7/>7)

76/70

68/76

0.410

Metastasis (no/yes)

87/59

72/72

0.100

Risk Stratification (low intermediate/high)

15/131

13/131

0.719

Platelet (median, interquartile range), 109/L

159.50 (134.00–198.00)

201.00 (167.50–238.50)

<0.001

Lymphocyte (median, interquartile range), 109/L

1.84 (1.57–2.21)

1.24 (1.02–1.51)

<0.001

  1. Abbreviations: PSA, prostate-specific antigen